Bioceltix Statistics

Total Valuation

Bioceltix has a market cap or net worth of PLN 509.19 million. The enterprise value is 477.28 million.

Market Cap	509.19M
Enterprise Value	477.28M

Important Dates

The last earnings date was Thursday, May 29, 2025.

Earnings Date	May 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 16.58% in one year.

Current Share Class	4.92M
Shares Outstanding	4.92M
Shares Change (YoY)	+16.58%
Shares Change (QoQ)	-13.90%
Owned by Insiders (%)	7.43%
Owned by Institutions (%)	18.46%
Float	3.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	14.71
P/TBV Ratio	14.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-32.95
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-29.09

Financial Position

The company has a current ratio of 8.23, with a Debt / Equity ratio of 0.02.

Current Ratio	8.23
Quick Ratio	8.04
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.04
Interest Coverage	-71.06

Financial Efficiency

Return on equity (ROE) is -70.87% and return on invested capital (ROIC) is -43.95%.

Return on Equity (ROE)	-70.87%
Return on Assets (ROA)	-37.63%
Return on Invested Capital (ROIC)	-43.95%
Return on Capital Employed (ROCE)	-42.12%
Revenue Per Employee	n/a
Profits Per Employee	-413,918
Employee Count	36
Asset Turnover	n/a
Inventory Turnover	68.53

Taxes

In the past 12 months, Bioceltix has paid 33,849 in taxes.

Income Tax	33,849
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +61.88% in the last 52 weeks. The beta is 1.45, so Bioceltix's price volatility has been higher than the market average.

Beta (5Y)	1.45
52-Week Price Change	+61.88%
50-Day Moving Average	113.05
200-Day Moving Average	91.41
Relative Strength Index (RSI)	40.94
Average Volume (20 Days)	8,162

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-1.55M
Operating Income	-14.70M
Pretax Income	-14.45M
Net Income	-14.49M
EBITDA	-14.05M
EBIT	-14.70M
Earnings Per Share (EPS)	-3.06

Full Income Statement

Balance Sheet

The company has 32.57 million in cash and 663,976 in debt, giving a net cash position of 31.91 million or 6.48 per share.

Cash & Cash Equivalents	32.57M
Total Debt	663,976
Net Cash	31.91M
Net Cash Per Share	6.48
Equity (Book Value)	34.62M
Book Value Per Share	7.03
Working Capital	31.86M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.96 million and capital expenditures -446,014, giving a free cash flow of -16.41 million.

Operating Cash Flow	-15.96M
Capital Expenditures	-446,014
Free Cash Flow	-16.41M
FCF Per Share	-3.33

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bioceltix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.58%
Shareholder Yield	n/a
Earnings Yield	-2.85%
FCF Yield	-3.22%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1